The fact that conditional SAE2 knockdown induced general mitotic defects and significantly delayed HCT116 and HT29 xenograft tumor growth (Fig 6 and S6 Fig) indicate SUMO pathway inhibition as a potential therapeutic approach in cancer. The gene discussed is UBA2; the disease is cancer.